70 Biggest Movers From Friday
Gainers
GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners.
48 Stocks Moving In Friday’s Mid-Day Session
Gainers
Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.
Opiant Pharmaceuticals Says To ‘Disregard’ Prior News Of $225M Licensing Agreement; Says Intial Release ‘Contains Incorrect Information
We are advised by Opiant Pharmaceuticals that journalists and other readers should disregard the news release, Opiant Pharmaceuticals and Hikma announce exclusive $225 million commercialisation and license agreement for
Opiant Pharmaceuticals And Hikma Earlier Announced Exclusive $225M Commercialization And License Agreement For OPNT003, Nasal Nalmefene, In Europe And UK
https://www.yahoo.com/now/opiant-pharmaceuticals-hikma-announce-exclusive-131500021.html
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
President Biden To Outline Strategy To Tackle Drug Addiction, Overdose: Reuters
U.S. President Joe Biden will reveal a new strategy today for dealing with drug addiction and overdoses to expand access…
OPNT: Data from OPNT003 Pharmacodynamic Trial in 2Q22…
By David Bautz, PhD
NASDAQ:OPNT
READ THE FULL OPNT RESEARCH REPORT
Looking Into Opiant Pharmaceuticals’s Return On Capital Employed
According to Benzinga Pro, during Q4, Opiant Pharmaceuticals (NASDAQ:OPNT) earned $752.33 thousand, a 77.98% increase from the preceding quarter. Opiant Pharmaceuticals's sales decreased to $13.80 million, a 15.54% change since Q3.
Opiant Pharmaceuticals: Q4 Earnings Insights
Opiant Pharmaceuticals (NASDAQ:OPNT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.